Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

被引：0
|
作者：
Tribich, Samuel
Maurice, James
机构：
来源：
FRONTLINE GASTROENTEROLOGY | 2020年 / 11卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [21] COST-UTILITY ANALYSIS OF ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN PATIENTS IN SPAIN
    Wang, S.
    Yang, H.
    Yang, M.
    Bao, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A670 - A670
  • [22] Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners
    Norton, Beth-Ann
    Sullivan, Anne
    Senior, Jennifer
    Candela, Ninfa
    Jason, Mary
    Weyant, Katherine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2022, 18 (04): : 438 - 445
  • [23] Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Lopez-Del Val, Alejandro
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 355 - 360
  • [24] An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
    Johnson, Amanda M.
    Loftus Jr, Edward V.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (12) : 1317 - 1327
  • [25] First Oral Drug for Moderate-To-Severe Ulcerative Colitis
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2018, 118 (09) : 22 - 22
  • [26] Spotlight: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
    Singh, Siddharth
    Loftus Jr, Edward V.
    Limketkai, Berkeley N.
    Haydek, John P.
    Agrawalm, Manasi
    Scott, Frank I.
    Ananthakrishnan, Ashwin N.
    GASTROENTEROLOGY, 2024, 167 (07) : 1344 - 1344
  • [27] Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis
    Miyoshi, Jun
    Matsuura, Minoru
    Hisamatsu, Tadakazu
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 1 - 8
  • [28] Pharmacokinetics of golimumab in patients with moderate-to-severe ulcerative colitis
    Berends, S.
    Strik, A.
    van Egmond, P.
    Brandse, H.
    Mathot, R.
    D'Haens, G.
    Lowenberg, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S424 - S424
  • [29] Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
    Freeman, Hugh J.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 451 - 456
  • [30] Comparative efficacy of vedolizumab and infliximab in patients with moderate-to-severe ulcerative colitis: a multicenter real world cohort study
    Sun, Y.
    Yang, H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1555 - i1555
12345